Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy

Journal of Clinical Investigation

Volumn 106, Issue 7, 2000, Pages 839-845

  Zhang, Linqi ^a   Chung, Chris ^a   Hu, Bor Shen ^a   He, Tian ^a   Guo, Yong ^a   Kim, Alexandria J ^a   Skulsky, Eva ^a   Jin, Xia ^a   Hurley, Arlene ^a   Ramratnam, Bharat ^a   Markowitz, Martin ^a   Ho, David D ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; REBOUND; VIREMIA; VIRUS ACTIVATION; VIRUS GENE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0033797161     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10565     Document Type: Article

References (37)

1. Hammer, S.M., et al 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
2. Gulick, R.M., et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
3. Perelson, A.S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387:188-191.
4. Markowitz, M., et al. 1999. The effect of commencing combination anti-retroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J. Infect. Dis. 179:527-537.
5. Palella, F.J., Jr., et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
6. Chiasson, M.A., et al. 1999. Declining HIV/AIDS mortality in New York City. J. Acquir. Immune Defic. Syndr. 21:59-64.
7. Chun, T.W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
8. Chun, T.W., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 94:13193-13197.
9. Chun, T.W., and Fauci, A.S. 1999. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. USA. 96:10958-10961.
10. Finzi, D., et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-1300.
11. Wong, J.K., et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1291-1295.
12. Gunthard, H.F., et al. 1999. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73:9404-9412.
13. Zhang, L., et al. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
14. Furtrado, M.R., et al. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:1614-1622.
15. Sharkey, M.E., et al. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6:76-81.
16. Ramratnam, B., et al. 2000. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6:82-85.
17. Lewin, S.R., et al. 1999. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J. Virol. 73:6099-6103.
18. Dornadula, G., et al. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 282:1627-1632.
19. Ho, D.D. 1998. Toward HIV eradication or remission: the tasks ahead. Science. 280:1866-1867.
20. Michie, C.A., McLean, A., Alcock, C., and Beverley, P.C. 1992. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 360:264-265.
21. Mohri, H., Bonhoeffer, S., Monard, S., Perelson, A.S., and Ho, D.D. 1998. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science. 279:1223-1227.
22. Hellerstein, M., et al. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:83-89.
23. Finzi, D., et al. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
24. Neumann, A.U., et al. 1999. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 13:677-683.
25. Harrigan, P.R., Whaley, M., and Montaner, J.S. 1999. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 13:F59-F62.
26. Garcia, F., et al. 1999. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 13:F79-F86.
27. Ortiz, G.M., et al. 1999. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104:R13-R18.
28. Davey, R.T., Jr., et al. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA. 96:15109-15114.
29. Vesanen, M., Stevens, C.E., Taylor, P.E., Rubinstein, P., and Saksela, K. 1996. Stability in controlling viral replication identities long-term non-progressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J. Virol. 70:9035-9040.
30. Zhang, L.Q., et al. 1993. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J. Virol. 67:3345-3356.
31. Simmonds, P., et al. 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64:864-872.
32. Higgins, D.G., Thompson, J.D., and Gibson, T.J. 1996. Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 266:383-402.
33. Felsenstein, J. 1988. Phylogenies from molecular sequences; inference and reliability. Annu. Rev. Genet. 22:521-565.
34. Saitou, N., and Nei, M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
35. Simmonds, P., Balfe, P., Ludlam, C.A., Bishop, J.O., and Brown, A.J. 1990. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J. Virol. 64:5840-5850.
36. Zhu, T., et al. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 261:1179-1181.
37. Chun, T.W., et al. 2000. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-761.